Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy

Yoshiki Nakae¹, Mizuki Hyuga¹, Yuta Terada², Wataru Kishimoto¹, Akiko Fukunaga¹, Sumie Tabata¹, Yoshitomo Maesako¹, Kenichi Komatsu³, Osamu Higuchi³, Toshinari Nakane⁴ and Nobuyoshi Arima¹

Abstract:
Autoimmune autonomic ganglionopathy is an autonomic disorder that occurs as a symptom of paraneoplastic neurological syndrome. To date, there have been no reports on multiple myeloma with autoimmune autonomic ganglionopathy. A 37-year-old Japanese woman suffered from orthostatic hypotension was diagnosed with multiple myeloma (IgG kappa type), and a serological examination revealed the presence of anti-ganglionic nicotinic acetylcholine receptor (anti-gAChR) antibodies. She was treated for multiple myeloma, as a result, the autonomic disturbance improved and her anti-gAChR antibody titer decreased to undetectable levels, despite the fact that she only achieved a partial remission of multiple myeloma. Treatment for multiple myeloma may improve autoimmune autonomic ganglionopathy.

Key words: multiple myeloma, autonomic disturbance, autoimmune autonomic ganglionopathy

(Intern Med 56: 3347-3351, 2017)
(DOI: 10.2169/internalmedicine.9096-17)

Introduction

Multiple myeloma (MM) is a plasma cell neoplasm that mainly develops in elderly patients and which is occasionally complicated by neuropathy. The neuropathies that occur due to MM include radiculopathy and spinal cord compression (which are induced by extramedullary plasmacytoma), peripheral neuropathy (which occurs due to amyloidosis), and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. However, there is only one reported case of MM with autonomic disturbance (1).

Autoimmune autonomic ganglionopathy (AAG) is an autoimmune disease that is induced by anti-ganglionic nicotinic acetylcholine receptor (anti-gAChR) antibodies, which bind to the acetylcholine receptor in the autonomic ganglia (2). The manifestations of AAG include symptoms associated with autonomic disturbance, such as orthostatic hypotension, disturbance of sweating, dysuria, and constipation. This disease occurs as a complication of paraneoplastic neurological syndrome associated with small cell lung carcinoma, thymoma, bladder carcinoma and rectal carcinoma (3-5). However, there are no reports of AAG occurring in association with MM. Moreover, MM rarely complicates autoimmune disease (6), and there are no reports of AAG with MM.

In the present report, we describe the first case of MM complicated by AAG. Treatment for MM, plasma exchange, and intravenous immunoglobulin reduced the anti-gAChR antibody titer and resulted in a recovery from autonomic disturbance, despite the fact that the patient experienced a partial remission (PR) of MM.

Case Report

A 37-year-old Japanese woman visited our hospital on foot complaining of walking difficulty of 2 months in dura-
out trisomy. There was no evidence of focal bone lesion on
fibroblast growth factor receptor (FGFR)3 fused gene with-
bone marrow revealed myeloma cells containing an IgH-
10
count, 5,600/μL; hemoglobin, 9.9g/dL; platelet count, 22.1×
she could not sit up due to orthostatic hypotension.
On admission, her height and body weight were 166.5 cm
and 57.9 kg, respectively. Her blood pressure was 118/72
mmHg, her pulse rate was 73 beats/min, and her body tem-
perature was 36.4°C. On physical examination, bilateral
numbness of the lower legs and feet, proximal lower limb
muscle weakness, a waddling gate, and Gower’s sign were
evident. However, cerebellar symptoms, central nervous sys-
tem manifestations, and changes of the deep tendon reflexes
were not evident. After admission, rapid onset orthostatic
hypotension appeared and on the 20th day of hospitalization
were consistent with a diagnosis of IgG kappa-type MM.
The T1 window of magnetic resonance imaging (MRI) re-
vealed that the right hamstring and gluteus maximus mus-
cles were more atrophic than the left (Fig. 2a). MRI with
short tau inversion recovery revealed areas of high intensity
in the lumbar paraspinal muscles, gluteus maximus muscle
and internal obturator muscle (Fig. 2b). A cerebrospinal
fluid examination revealed the following: total protein, 88.9
mg/dL; albumin, 364.2 mg/L; glucose, 55 mg/dL; nucleated
cells, 13 cells (12 mononucleated cells, one multinucleated
cell). The coefficient of variation of R-R (CV-RR) interval
on electrocardiography was revealed to be 1.55%, which
showed an autonomic disturbance. An electromyogram re-
vealed that the lumbar paraspinal muscle contraction was
impaired. A nerve conduction velocity study revealed that
the motor and sensory nerves of the leg had a low amplitude
and a low conduction velocity. These results indicated an
axonal disorder and demyelination of the peripheral nerves.
Moreover, serological examinations were positive for anti-
α3 subunit gAChR antibodies, and anti-β4 subunit gAChR anti-
bodies (8). These findings were consistent with a diagnosis
of “AAG with peripheral neuropathy”.
On the 25th day of hospitalization, the patient was treated
for symptomatic MM with BD [a 5-week cycle of borte-
zbomib (1.3 mg/m2), via subcutaneous injection on days 1, 8,
15 and 22] plus dexamethasone (20 mg/body, orally on days
1, 2, 8, 9, 15, 16, 22 and 23]) because AAG is reported to
be one of the paraneoplastic neurological syndromes (3-5).
After two courses of BD, 18 rounds of plasma exchange,
and intravenous immunoglobulin, the patient’s free kappa
chain level decreased from 9,650.0 mg/L to 138.0 mg/L.
This indicated a PR (of the patient’s MM), as defined by the
International Myeloma Working Group (9). Accordingly, the
patient could sit down on her own, her CV-RR interval was
improved, and her anti-α3 subunit gAChR antibody and
anti-β4 subunit gAChR antibody titters became negative on
the 72nd day of hospitalization (Fig. 3). However, borte-
Figure 1. a) Serum immuno electrophoresis revealed IgG kappa type monoclonal protein. b) A bone
marrow smear revealed increased plasma cells in the nucleated cells.
Figure 2. a) The right hamstring and gluteus maximus muscles were more atrophic than the muscles on the left in the T1 window of MRI. The upper image shows the gluteus maximus muscle; the lower image shows the internal obturator muscle. b) The upper image shows the lumbar paraspinal muscles, the middle image shows the internal obturator muscle, and lower image shows the gluteus maximus muscle. A high intensity area is observed in the right lumbar paraspinal muscles, both internal obturator muscles and the right gluteus maximus muscle in the STIR window of MRI.

Figure 3. The clinical course of the patient. The left vertical axis represents the percentage of CV-RR, the right vertical axis represents the kappa chain and lambda chain. The horizontal axis represents the days after admission. K chain: kappa chain, L chain: lambda chain, BD: bortezomib+dexamethasone, IVIG: intravenous immunoglobulin, Rd: lenalidomide+dexamethasone, HDD: high-dose dexamethasone, PE: plasma exchange, #1: anti-α3 subunit gAChR antibody and anti-β4 subunit gAChR antibody were positive, #2: anti-α3 subunit gAChR antibody and anti-β4 subunit gAChR antibody were negative.
zomib worsened her peripheral sensory neuropathy (CTCAE version 4.0: grade III), and was therefore discontinued. Unfortunately, LD [a 4-week cycle of lenalidomide (5 mg/body, orally on days 1-21) plus dexamethasone (20 mg/body, orally on days 1-4 and 15-18)] also worsened her sensory peripheral neuropathy (CTCAE version 4.0: grade III). Thus, she was treated with high-dose dexamethasone [This consisted of a 4-week cycle of dexamethasone (20 mg/body, orally on days 1-4, 9-12 and 17-20)] and rehabilitation. As a result, she was discharged on foot on the 138th day of hospitalization.

**Discussion**

The present case was significant for two findings. First, MM and AAG were found to coexist. Second, treatment for MM, plasma exchange, and intravenous immunoglobulin induced a good remission of AAG with a reduction of the anti-gAChR antibody titer, despite the fact that only PR of MM was achieved.

This is the first report on the coexistence of MM and AAG in a patient. MM has been reported to induce peripheral neuropathy; this symptom occurs in 7.2% of MM patients (10). Moreover, treatment-related peripheral neuropathy has been reported to occur in association with bortezomib (11), thalidomide (12), lenalidomide (13), and pomalidomide (14). In the previously mentioned case of MM with autonomic disturbance (1), the cause of the autonomic disturbance was not evident. Thus, this represents the first case of MM with autonomic disturbance in which the cause was evident. Is this case extremely rare? It is possible that similar cases occur more frequently but are not reported because, in the clinical setting, many hematologists do not take the initiative to perform a neurological examination in cases in which MM is aggravated by events, such as bone fracture, or when a patient’s activities of daily living are impaired by peripheral neuropathy. Autonomic disturbance may be hidden in such a case; thus, MM with autonomic disturbance may require more than hematology-specific knowledge. There may be other cases of treatable autonomic disturbance that occur in association with MM.

The second point of clinical significance is that treatment for MM, plasma exchange, and intravenous immunoglobulin induced a good remission of AAG and reduced the patient’s anti-gAChR antibody titer, despite the fact that only PR of MM was achieved. The treatments for AAG include immunosuppression therapy (such as steroids, azathioprine, rituximab (15), and mycophenolate mofetil), intravenous immunoglobulin and plasma exchange. The role of immunosuppression therapy is to suppress the production of anti-gAChR antibodies, plasma exchange performed to clear up the anti-gAChR antibodies in the serum, and intravenous immunoglobulin is administered to capture anti-gAChR antibodies in the serum. Nakane et al. reported that six of seven cases responded to immunosuppression therapy (16), and Iodice et al. also reported that all six of their cases responded to immunosuppression therapy (17). In the present case, treatment for MM played the effect of immunosuppression therapy for AAG; thus, the patient recovered from orthostatic hypotension and her anti-gAChR antibody titer remained below the limit of detection for at least 1 year after discharge. This case was definitely diagnosed as AAG complicated with MM. We must therefore consider the possibility that an abnormal monoclonal protein secreted by myeloma cells bound directly to the ganglionic nicotinic acetylcholine receptors. If the monoclonal protein bound directly to the ganglionic nicotinic acetylcholine receptors, autonomic disturbance and anti-gACgR antibodies would have remained because the patient’s MM was only in PR-meaning that the monoclonal protein obviously remained. Thus, we did not examine whether the monoclonal proteins or ganglionic nicotinic acetylcholine receptors were directly bound, the monoclonal protein might not bind to ganglionic nicotinic acetylcholine receptor. Treatment for MM may be one option for achieving immunosuppression in AAG patients who are resistant to conventional treatment.

MM is a plasma cell neoplasm that produces abnormal immunoglobulin. The purpose of treatment is to reduce the number of abnormal plasma cells. Immunosuppression occurs as an adverse event in patients undergoing MM treatment because the numbers of normal plasma cells and other immunocompetent cells are also reduced by the treatment for MM. However, this indicates the possibility that treatment for MM may be effective for treating autoimmune diseases. Bortezomib has been used in the treatment of systemic lupus erythematosus (18), lenalidomide has been used in the treatment of systemic lupus erythematosus (19-22) and Behcet’s disease (22), and high-dose dexamethasone has been used in the treatment of autoimmune thrombocytopenia (23-25). These results and the present case indicate the possibility that treatment for MM might be effective in the treatment of refractory autoimmune disease.

In conclusion, MM may accompany AAG. In the present case, treatment for MM effectively improved the patient’s AAG and autonomic disturbance. We must be aware of the possibility of hidden autonomic disturbance in MM patients, which may be treatable by treatment regimens that are typically used for MM, plasma exchange, and intravenous immunoglobulin. Further reports should be accumulated to determine whether the incidence of hidden autonomic disturbance in MM patients is higher than previously thought, and to determine the best treatment regimen for autonomic disturbance in patients with MM.

**The authors state that they have no Conflict of Interest (COI).**

**References**

1. Goldstein DS, McRae A, Holmes C, Dalakas MC. Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome. Clin Auton Res 6: 17-21, 1996.
2. Klein CM, Vernino S, Lennon VA, et al. The spectrum of autoim-
26. Godeau B, Bierling P, Oksenhendler E, Castaigne S, Deconinck E, Dubois R. Cytoreductive bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74: 1474-1478, 2015.

27. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 14: R265, 2012.

28. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 145: 303-306, 2009.

29. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 66: 571-582, 2012.

30. Green J, Upjohn E, McCormack C, Zeldis J, Prince HM. Successful treatment of Behçet’s disease with lenalidomide. Br J Dermatol 158: 197-198, 2008.

31. Dubeld P, van der Heul C, Hillen HF. Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP). Neth J Med 39: 6-10, 1991.

32. Godeau B, Bierling P, Oksenhendler E, Castaigne S, Deconinck E, Wechsler B. High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura. Am J Hematol 51: 334, 1996.

33. Zhan Y, Zou S, Hua F, et al. High-dose dexamethasone modulates serum cytokine profile in patients with primary immune thrombocytopenia. Immunol Lett 160: 33-38, 2014.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).